Key Viral Hepatitis Studies Influencing My Practice Following AASLD 2022

November 4-8, 2022; Washington, DC
Read expert faculty members’ summaries of HBV, HDV, and HCV studies, including data on HBV therapy during pregnancy, HBV therapeutic vaccines and progress toward an HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and current status of the cascade of care.
Nancy Reau, MD
Stefan Zeuzem, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.36 MB
Released: November 16, 2022

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.

Related Content

Dr Maria Buti shares strategies to ensure patients with HBV are promptly screened for HDV, from Clinical Care Options (CCO)

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 12, 2023 Expired: January 11, 2024

Download this slideset on overcoming barriers in HDV screening, from Clinical Care Options (CCO)

Maria Buti, MD Released: January 5, 2023

Learn from Dr Nancy Reau why we may want to challenge current guidelines on HDV screening, from Clinical Care Options (CCO)

Nancy Reau, MD Released: January 5, 2023

Dr Tatyana Kushner provides special considerations in diagnosing HDV through a patient case, from Clinical Care Options (CCO)

Tatyana Kushner, MD, MSCE Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 21, 2022 Expired: December 20, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings